PHYSICAL PHARMACEUTICA LLC
Physical Pharmaceutica (PhysPharm) is a pharmaceutical research and development company founded in 2007, leveraging world-class expertise and patented technologies to solve complex formulation challenges where conventional methods fail. They specialize in formulation design, biopharmaceutics, pharmacokinetics, and testing, offering a unique, multi-disciplinary approach combining physical science, chemistry, biopharmaceutics, and computational modeling. PhysPharm's mission is to deliver science and innovation that produce tangible results, focusing on data that is useful for project development or regulatory evaluation. Their proprietary technologies are exclusive and robust, with a proven track record including contributions to a filed ANDA for cyclosporine ophthalmic emulsion. They collaborate with pharmaceutical companies and the FDA, offering services like in vitro release testing, drug distribution analysis, bioequivalence studies, and developing manufacturing technologies for amorphous solid dispersions. Their key personnel include Robert A. Bellantone, Ph.D., a founding partner and President and Chief Scientific Officer, who possesses a unique background as a physicist and registered pharmacist, and Marissa J. Kaplan, M.S., Senior Scientist, R&D Lead.
PHYSICAL PHARMACEUTICA LLC
Physical Pharmaceutica (PhysPharm) is a pharmaceutical research and development company founded in 2007, leveraging world-class expertise and patented technologies to solve complex formulation challenges where conventional methods fail. They specialize in formulation design, biopharmaceutics, pharmacokinetics, and testing, offering a unique, multi-disciplinary approach combining physical science, chemistry, biopharmaceutics, and computational modeling. PhysPharm's mission is to deliver science and innovation that produce tangible results, focusing on data that is useful for project development or regulatory evaluation. Their proprietary technologies are exclusive and robust, with a proven track record including contributions to a filed ANDA for cyclosporine ophthalmic emulsion. They collaborate with pharmaceutical companies and the FDA, offering services like in vitro release testing, drug distribution analysis, bioequivalence studies, and developing manufacturing technologies for amorphous solid dispersions. Their key personnel include Robert A. Bellantone, Ph.D., a founding partner and President and Chief Scientific Officer, who possesses a unique background as a physicist and registered pharmacist, and Marissa J. Kaplan, M.S., Senior Scientist, R&D Lead.